| Abstract: | Pharmacological treatment of Chagas disease with benznidazole (BNZ) is effective in
children in all stages, but it is controversial in chronically infected adults. We
report the pharmacokinetics and pharmacodynamics in six adult patients with Chagas
disease treated with the new BNZ formulation (ABARAX®) in doses between
2.5-5.5 mg/Kg/day. All but one patient had plasmatic BNZ concentrations within the
expected range. All patients finalised treatment with nondetectable
Trypanosoma cruziquantitative polymerase chain reaction, which
remained nondetectable at the six month follow-up. Our data suggests parasitological
responses with the new BNZ and supports the hypothesis that treatment protocols with
lower BNZ doses may be effective. |
